Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Arnd Nusch"'
Autor:
Fabio Malavasi, Anja Führer, Holger Nückel, Jan Dürig, Tarik Möröy, Naser Kalhori, Silvia Deaglio, Roland Rudolph, Tanja Hölter, Ulrich Dührsen, Elisabeth Kruse, Andreas Hüttmann, Arnd Nusch, Katja Halfmeyer, Ludger Klein-Hitpass
Publikováno v:
Blood. 101:2748-2755
B-cell chronic lymphocytic leukemia (B-CLL) is a heterogenous disease with a highly variable clinical course. Recent studies have shown that CD38 surface expression on the malignant cell clone may serve as a prognostic marker in that CD38+ patients w
Autor:
Jacqueline Rauh, Christian Taverna, Martin Schmidt-Hieber, Paul Jehner, Roger von Moos, Christoph Driessen, Elke Hiendlmeyer, Arnd Nusch, Steffen Doerfel, Richard Cathomas, Mario Bargetzi, Mathias Schmid, Ulrich Mey, Axel Ruefer, Andreas Schwarzer, Natalie Fischer, Heike Schwarb, Felicitas Hitz, Wolfgang Knauf, Wolfram Brugger, Tobias Dechow, Carsten Ziske
Publikováno v:
Blood. 124:4779-4779
Background High quality response [very good partial remission (VGPR), complete remission (CR)] is associated with improved long-term outcome in multiple myeloma (MM) therapy. Lenalidomide (Len)/ dexamethasone (Dex) (Rd) is considered a standard 2nd-l
Publikováno v:
Blood. 120:3666-3666
Abstract 3666 Introduction With the FDA and EMA approval of Bendamustine a new treatment option has recently become available to patients (pts) with indolent (low-grade) non-Hodgkin lymphoma (iNHL). Clinical registries provide insight into real-life
Publikováno v:
Blood. 120:4605-4605
Abstract 4605 Introduction With the FDA and EMA approval of Bendamustine and Rituximab new treatment options have recently become available to patients (pts) with chronic lymphocytic leukemia (CLL). Clinical registries provide insight into real-life